These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 9247754)

  • 21. [The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure].
    Bernadet-Monrozies P; Rostaing L; Kamar N; Durand D
    Presse Med; 2002 Nov; 31(36):1714-20. PubMed ID: 12467154
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Vascular hypertrophy and albumin permeability in a rat model combining hypertension and diabetes mellitus. Effects of calcium antagonism, angiotensin converting enzyme inhibition, and angiotensin II-AT1-receptor blockade.
    Hulthén UL; Cao Z; Rumble JR; Cooper ME; Johnston CI
    Am J Hypertens; 1996 Sep; 9(9):895-901. PubMed ID: 8879346
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Disparate effects of angiotensin II antagonists and calcium channel blockers on albuminuria in experimental diabetes and hypertension: potential role of nephrin.
    Davis BJ; Cao Z; de Gasparo M; Kawachi H; Cooper ME; Allen TJ
    J Hypertens; 2003 Jan; 21(1):209-16. PubMed ID: 12544453
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antihypertensive therapy in experimental diabetes.
    Anderson S
    J Am Soc Nephrol; 1992 Oct; 3(4 Suppl):S86-90. PubMed ID: 1360846
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Preventing end-stage renal disease.
    Mogensen CE
    Diabet Med; 1998; 15 Suppl 4():S51-6. PubMed ID: 9868993
    [TBL] [Abstract][Full Text] [Related]  

  • 26. ACE inhibitors and antihypertensive treatment in diabetes: focus on microalbuminuria and macrovascular disease.
    Mogensen CE
    J Renin Angiotensin Aldosterone Syst; 2000 Sep; 1(3):234-9. PubMed ID: 11881030
    [No Abstract]   [Full Text] [Related]  

  • 27. Effects of the angiotensin II type 1 receptor antagonist candesartan, compared with angiotensin-converting enzyme inhibitors, on the urinary excretion of albumin and type IV collagen in patients with diabetic nephropathy.
    Sato A; Tabata M; Hayashi K; Saruta T
    Clin Exp Nephrol; 2003 Sep; 7(3):215-20. PubMed ID: 14586718
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The management of diabetic proteinuria. Which antihypertensive agent?
    Cooper ME; Doyle AE
    Drugs Aging; 1992; 2(4):301-9. PubMed ID: 1504444
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Angiotensin converting enzyme inhibition and calcium channel blockade in incipient diabetic nephropathy. The Melbourne Diabetic Nephropathy Study Group.
    Jerums G; Allen TJ; Tsalamandris C; Cooper ME
    Kidney Int; 1992 Apr; 41(4):904-11. PubMed ID: 1513112
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combination antihypertensive therapy in the treatment of diabetic nephropathy.
    Boner G; Cao Z; Cooper ME
    Diabetes Technol Ther; 2002; 4(3):313-21. PubMed ID: 12165170
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of different ACE inhibitor combinations on albuminuria: results of the GUARD study.
    Bakris GL; Toto RD; McCullough PA; Rocha R; Purkayastha D; Davis P;
    Kidney Int; 2008 Jun; 73(11):1303-9. PubMed ID: 18354383
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evolving therapeutic strategies for retarding progression of diabetic nephropathy--an update for 2002.
    Epstein M
    Acta Diabetol; 2002 Jun; 39 Suppl 2():S41-5. PubMed ID: 12222627
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Recent advances in pharmacological management of hypertension in diabetic patients with nephropathy. Effects of antihypertensive drugs on kidney function and insulin sensitivity.
    Baba T; Ishizaki T
    Drugs; 1992 Apr; 43(4):464-89. PubMed ID: 1377114
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Renal protection in diabetes--an emerging role for calcium antagonists.
    Parving HH; Tarnow L; Rossing P
    Cardiology; 1997; 88 Suppl 3():56-62. PubMed ID: 9397296
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of an ACE inhibitor combined with a calcium channel blocker on progression of diabetic nephropathy.
    Bakris G; White D
    J Hum Hypertens; 1997 Jan; 11(1):35-8. PubMed ID: 9111155
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment of the diabetic patient: focus on cardiovascular and renal risk reduction.
    Abbott KC; Bakris GL
    Prog Brain Res; 2002; 139():289-98. PubMed ID: 12436944
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Blood pressure lowering for the prevention and treatment of diabetic kidney disease.
    Thomas MC; Atkins RC
    Drugs; 2006; 66(17):2213-34. PubMed ID: 17137404
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Is antihypertensive treatment the same for NIDDM and IDDM patients?
    Parving HH
    Diabetes Res Clin Pract; 1998 Apr; 39 Suppl():S43-7. PubMed ID: 9649959
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The use of antihypertensive agents in prevention and treatment of diabetic nephropathy.
    Parving HH; Rossing P
    Curr Opin Nephrol Hypertens; 1994 May; 3(3):292-300. PubMed ID: 7922255
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of antihypertensive therapy on progression of diabetic nephropathy.
    Luño J; Garcia de Vinuesa S; Gomez-Campdera F; Lorenzo I; Valderrábano F
    Kidney Int Suppl; 1998 Dec; 68():S112-9. PubMed ID: 9839294
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.